Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
GME GameStop Corp
XELA Exela Technologies Inc
ARKK ARK Innovation ETF
NVVEW Nuvve Holding Equity Warrants Exp 19 March 2026 *W EXP 03/19/2026
BEPH Brookfield BRP Holdings (Canada) Inc
CHKP Check Point Software Technologies Ltd
FDX FedEx Corp
VLON Vallon Pharmaceuticals Inc
HCNEU Jaws Hurricane Acquisition Corp

Health Care : Biotechnology |
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

Closing Price
Day's Change
-0.17 (-2.76%)
B/A Size
Day's High
Day's Low

10-day average volume:

Tesla hits record quarterly profit, says supply-chain snags kept its factories from running 'full speed'

8:32 am ET October 21, 2021 (MarketWatch)

Claudia Assis

Tesla tweaks outlook, announces new battery chemistry

Tesla Inc. late Wednesday reported record quarterly profit and sales, but spooked investors by tweaking its outlook and saying that chip shortages, port congestion and other supply-chain and infrastructure challenges are preventing its factories from running at full speed.

Tesla (TSLA) said it earned $1.6 billion, or $1.44 a share, in the third quarter, compared with $331 million, or 27 cents a share, in the year-ago period. Adjusted for one-time items, the EV maker earned $1.86 a share.

Revenue rose 57% to $13.8 billion, from $8.8 billion a year ago.

Analysts polled by FactSet expected Tesla to report adjusted earnings of $1.62 a share on sales of $14 billion.

Related: Ford stock rallies to highest in 6 years

The ongoing chips and auto parts shortages and problems with logistics have meant that Tesla hasn't run its factories "at full capacity," Zach Kirkhorn, Tesla's chief financial officer, said in a call with investors and analysts after the results.

People want to buy a Tesla, but "we are not able to increase production capacity fast enough," he said.

"We're trying as hard as we can to maximize that capacity and to be able to meet the demand that we're receiving," but depending on the type of car desired, someone buying a Tesla today could end up waiting a couple of months, or a couple of quarters, he said.

Tesla has roughly doubled its deliveries this year, but that has been "exceptionally difficult to achieve," he said.

Chief Executive Elon Musk was not in the call. After Tesla's second-quarter results in late July, Musk told Wall Street he'd be unlikely be on future Tesla earnings calls "unless there's something important I need to say."

Shares of Tesla fell more than 1% in the extended session Wednesday, after ending the regular trading day up 0.2%. The shares pared some losses toward the end of the after-hours trading.

The "muted" reaction as expectations for a beat were priced in, CFRA analyst Garrett Nelson said. The company saying that the pace of its growth would be largely determined by outside factors also "gives investors pause," he said.

See also:'There's limits on how big you can scale in the Bay Area;' Musk moving Tesla HQ to Texas from California

Tesla removed language in its outlook that had kept it optimistic about 2021's growth.

The EV maker has shied away from specific sales guidance this year, and on Wednesday repeated the broad goal of achieving a 50% average annual growth in sales "over a multi-year horizon."

But it removed a sentence had led Tesla investors to believe this year could be even better: "In some years it may grow faster, which we expect to be the case in 2021."

That rosier hope for this year was written in previous Tesla's letters to shareholders as recently as the second quarter letter, but was absent from Wednesday's letter.

At the call, Kirkhorn sought to reassure investors and he reiterated the 50% increase at least in production as a goal for the year, despite the supply-chain bottlenecks.

"I think that will be a difficult goal but that's the goal that the internal team has," he said. Tesla wants to get "millions of cars per year over the next couple of years," and ultimately be able to achieve a rate of 20 million cars per year.

"We're going to grow as quickly as is feasible possibly with an eye towards 50% annual growth rate," Kirkhorn said.

The company said it had $1.3 billion in operating cash flow, minus capital expenditures, in the third quarter. In total, its cash and equivalents fell by $164 million to $16.1 billion in the third quarter.

Read: More electric pickup trucks are coming to market. But who will buy them?

Operating profits rose mostly thanks to sales volume growth and cost reductions, but that was offset by rising expenses, lower revenue from regulatory credits, additional costs related to the supply-chain snags and a bitcoin-related impairment of $51 million, the company said.

On the technical side, the big news was that Tesla said it was shifting to a cobalt-free battery chemistry for all its standard-range vehicles. Lithium iron phosphate batteries had been an option for certain Model 3 trims.

Cobalt is viewed as the highest supply-chain risk for electric vehicles in the short and medium term, the Energy Department said earlier this year. "There are economic, security, and societal drivers to reduce (cobalt) content," and, moreover, there are no large reserves of the metal in the U.S., it said.

Tesla stock has gained 23% so far this year, compared with gains of around 21% for the S&P 500 index .

-Claudia Assis


(END) Dow Jones Newswires

October 21, 2021 08:32 ET (12:32 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.